Hunan Fangsheng Pharmaceutical Co., Ltd. (603998.SS)
CNY 10.84
(0.18%)
CNY 10.84
(0.18%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.49 Billion CNY | 5.52% |
| 2022 | 1.41 Billion CNY | 0.95% |
| 2021 | 1.4 Billion CNY | 43.37% |
| 2020 | 977.04 Million CNY | 23.29% |
| 2019 | 792.5 Million CNY | 49.58% |
| 2018 | 529.81 Million CNY | 57.97% |
| 2017 | 335.38 Million CNY | 15.13% |
| 2016 | 291.3 Million CNY | 115.88% |
| 2015 | 134.94 Million CNY | 56.03% |
| 2014 | 86.48 Million CNY | 8.79% |
| 2013 | 79.49 Million CNY | 39.51% |
| 2012 | 56.98 Million CNY | -17.28% |
| 2011 | 68.88 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 1.57 Billion CNY | -1.61% |
| 2024 Q2 | 1.6 Billion CNY | 0.32% |
| 2024 Q1 | 1.59 Billion CNY | 6.92% |
| 2023 Q3 | 1.54 Billion CNY | 1.8% |
| 2023 Q4 | 1.49 Billion CNY | -3.2% |
| 2023 Q1 | 1.39 Billion CNY | -1.54% |
| 2023 Q2 | 1.51 Billion CNY | 8.76% |
| 2023 FY | 1.49 Billion CNY | 5.52% |
| 2022 Q4 | 1.41 Billion CNY | 33.02% |
| 2022 Q3 | 1.06 Billion CNY | -40.9% |
| 2022 Q2 | 1.79 Billion CNY | 20.53% |
| 2022 Q1 | 1.49 Billion CNY | 6.53% |
| 2022 FY | 1.41 Billion CNY | 0.95% |
| 2021 Q4 | 1.4 Billion CNY | 10.28% |
| 2021 Q2 | 1.11 Billion CNY | 16.07% |
| 2021 Q3 | 1.27 Billion CNY | 14.23% |
| 2021 FY | 1.4 Billion CNY | 43.37% |
| 2021 Q1 | 958.05 Million CNY | -1.94% |
| 2020 Q1 | 855 Million CNY | 7.89% |
| 2020 Q2 | 777.22 Million CNY | -9.1% |
| 2020 Q3 | 842.64 Million CNY | 8.42% |
| 2020 Q4 | 977.04 Million CNY | 15.95% |
| 2020 FY | 977.04 Million CNY | 23.29% |
| 2019 Q3 | 706.27 Million CNY | 10.54% |
| 2019 Q2 | 638.91 Million CNY | 17.7% |
| 2019 Q4 | 792.5 Million CNY | 12.21% |
| 2019 FY | 792.5 Million CNY | 49.58% |
| 2019 Q1 | 542.85 Million CNY | 2.46% |
| 2018 Q1 | 348.68 Million CNY | 3.96% |
| 2018 FY | 529.81 Million CNY | 57.97% |
| 2018 Q4 | 529.81 Million CNY | -7.98% |
| 2018 Q3 | 575.72 Million CNY | 29.61% |
| 2018 Q2 | 444.2 Million CNY | 27.4% |
| 2017 Q4 | 335.38 Million CNY | -18.12% |
| 2017 Q1 | 293.61 Million CNY | 0.79% |
| 2017 Q3 | 409.58 Million CNY | 35.1% |
| 2017 FY | 335.38 Million CNY | 15.13% |
| 2017 Q2 | 303.17 Million CNY | 3.25% |
| 2016 Q1 | 112.52 Million CNY | -16.61% |
| 2016 FY | 291.3 Million CNY | 115.88% |
| 2016 Q3 | 166.68 Million CNY | -0.99% |
| 2016 Q2 | 168.34 Million CNY | 49.6% |
| 2016 Q4 | 291.3 Million CNY | 74.77% |
| 2015 Q2 | 94.72 Million CNY | 12.66% |
| 2015 Q1 | 84.08 Million CNY | -2.78% |
| 2015 Q4 | 134.94 Million CNY | 62.85% |
| 2015 FY | 134.94 Million CNY | 56.03% |
| 2015 Q3 | 82.86 Million CNY | -12.52% |
| 2014 Q2 | 69.52 Million CNY | 0.0% |
| 2014 Q1 | - CNY | -100.0% |
| 2014 Q3 | 76.87 Million CNY | 10.56% |
| 2014 Q4 | 86.48 Million CNY | 12.5% |
| 2014 FY | 86.48 Million CNY | 8.79% |
| 2013 FY | 79.49 Million CNY | 39.51% |
| 2013 Q4 | 79.49 Million CNY | 0.0% |
| 2012 FY | 56.98 Million CNY | -17.28% |
| 2011 FY | 68.88 Million CNY | 0.0% |